Once-daily formulation of dexmethylphenidate achieved primary endpoint (p < 0.001) with consistent symptom relief up to 12 hours post-doseKANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, announced today that the positive Phase 3 results from its pivotal trial of CTx-1301 (dexmethylphenid ...

KANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical products utilizing its proprietary Precision Timed Release™ (PTR™) drug-delivery platform, today announced that data from its lead ADHD candidate CTx-1301 (dexmethylphenidate HCl) has been selected for podium presentation at the American Academy of Child and Adolescent Psychiatry (AACAP) Annual Meeting in Chicago. This recogniti ...

Group 1: Government Actions and Claims - The US administration, led by President Trump, aims to address rising autism diagnoses by targeting the OTC painkiller Tylenol, linking its use by pregnant women to increased autism risk [1][4][5] - The administration plans to change safety labels for acetaminophen and launch a public service campaign to inform families about the potential risks [5][6] Group 2: Scientific Evidence and Expert Opinions - The administration cited large-scale studies suggesting a link between in-utero acetaminophen exposure and autism, but experts have called for more research and caution in interpreting these findings [6][7] - Major health organizations, including the WHO and various national health bodies, have refuted the claims, stating there is no conclusive evidence linking Tylenol to autism [8][9] Group 3: Legal Context and Market Implications - Previous lawsuits against Tylenol's marketer, Kenvue, claiming links to autism were dismissed in 2023 due to inadequate scientific evidence, but appeals are planned [11][12] - In India, paracetamol remains a widely used OTC drug, with significant sales figures, but concerns over its dosage persist, leading to regulatory actions against certain combinations [12]

Core Insights - Supernus Pharmaceuticals is launching a new video series featuring Jay Glazer and his wife Rosie, focusing on the impact of ADHD on relationships and the role of Qelbree in managing ADHD symptoms [1][2][3] - The series aims to foster open discussions about ADHD, sharing practical strategies for symptom management and insights from both Jay and Rosie [2][3] Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing treatments for central nervous system (CNS) diseases, including ADHD [11][12] - The company has a diverse neuroscience portfolio that includes approved treatments for various CNS disorders, and is actively developing new potential treatments for conditions such as epilepsy and depression [12] Product Information - Qelbree (viloxazine extended-release capsules) is a non-stimulant prescription medication used to treat ADHD in individuals aged 6 years and older [5][10] - Qelbree is available in three dosages: 100 mg, 150 mg, and 200 mg capsules [10]

Company Overview - Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases [15] - The company has a diverse neuroscience portfolio that includes approved treatments for ADHD, dyskinesia in Parkinson's disease, epilepsy, migraine, and other CNS disorders [16] Product Information - Qelbree (viloxazine extended-release capsules) is a prescription medicine used to treat ADHD in adults and children aged 6 years and older [6] - Qelbree is a novel, once-a-day, non-stimulant approach for ADHD treatment and is the first non-stimulant approved for adults with ADHD in 20 years [4] - As a non-stimulant, Qelbree has no evidence of abuse or misuse and can be conveniently refilled without needing a new prescription each month [4] Campaign and Awareness - The 'Ms. Represented' campaign, in partnership with Busy Philipps, aims to empower women with ADHD to understand their symptoms and seek help [1][4] - The campaign highlights the often-misrepresented experiences of women with ADHD, focusing on the differences in symptom presentation between genders [2][3] - Increased awareness of ADHD symptoms among females is leading to more women seeking diagnosis and treatment [3] Market Insights - Studies indicate that boys are twice as likely as girls to be diagnosed with ADHD, resulting in many women remaining undiagnosed or misdiagnosed until adulthood [3] - The campaign seeks to address the disparity in ADHD diagnosis and treatment between males and females [4]